Investment & Fund Management
a venture capital firm supported by the European Investment
Full Credential Description
Kiro, a French deeptech company, faced significant challenges in the healthcare sector, particularly in making complex medical data from clinical laboratories more comprehensible for both patients and healthcare professionals. The intricacies of lab results often overwhelmed users, necessitating a solution that could simplify data interpretation while considering multiple evolving data points. Kiro aimed to leverage artificial intelligence to enhance the understanding of lab results, thereby empowering healthcare professionals to make more informed decisions without taking over the diagnostic process.
In late 2019, Kiro secured seed financing through an equity investment from Kurma Partners, a venture capital firm supported by the European Investment Fund (EIF). This funding enabled Kiro to expand its team by hiring seven new employees and to advance the development of its AI-driven product. The investment facilitated the creation of the initial layer of their solution, which is currently undergoing market fit testing in France, with plans for future international expansion, particularly into the US.
Additionally, Kiro has been proactive in addressing the Covid-19 pandemic by collaborating with the AP-HM hospital group in Marseille on a research project aimed at utilizing their AI technology to identify low-level signals in Covid pathology. This initiative underscores Kiro's commitment to harnessing AI for improved patient care and healthcare services. The overarching goal of Kiro is to provide targeted and optimal care at scale, utilizing machine learning to enhance the capabilities of healthcare professionals and ultimately improve patient outcomes.